Prophylactic mastectomy for BRCA1/2 carriers:: Progress and more questions

被引：30

作者：

Hartmann, LC ^{[1
]}

Degnim, A

Schaid, DJ

机构：

[1] Mayo Clin Canc Ctr, Dept Oncol, Rochester, MN 55905 USA

[2] Mayo Clin Canc Ctr, Dept Gen Surg, Rochester, MN USA

[3] Mayo Clin Canc Ctr, Mayo Clin Coll Med, Dept Hlth Sci Res, Div Biostat, Rochester, MN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 06期

关键词：

D O I：

10.1200/JCO.2004.01.925

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：981 / 983

页数：3

共 16 条

[1] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2 [J].

Burke, W ;

Daly, M ;

Garber, J ;

Botkin, J ;

Kahn, MJE ;

Lynch, P ;

McTierman, A ;

Offit, K ;

Perlman, J ;

Petersen, G ;

Thomson, E ;

Varricchio, C .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12) :997-1003

[2] American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition [J].

Chlebowski, RT ;

Col, N ;

Winer, EP ;

Collyar, DE ;

Cummings, SR ;

Vogel, VG ;

Burstein, HJ ;

Eisen, A ;

Lipkus, I ;

Pfister, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3328-3343

[3] Overview of the main outcomes in breast-cancer prevention trials [J].

Cuzick, J ;

Powles, T ;

Veronesi, U ;

Forbes, J ;

Edwards, R ;

Ashley, S ;

Boyle, P .

LANCET, 2003, 361 (9354) :296-300

[4]

ELDAR S, 1984, AM J SURG, V148, P692, DOI 10.1016/0002-9610(84)90352-0

[5] Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23 [J].

Fisher, B ;

Anderson, S ;

Tan-Chiu, E ;

Wolmark, N ;

Wickerham, DL ;

Fisher, ER ;

Dimitrov, NV ;

Atkins, JN ;

Abramson, N ;

Merajver, S ;

Romond, EH ;

Kardinal, CG ;

Shibata, HR ;

Margolese, RG ;

Farrar, WB .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :931-942

[6] FAILURE OF SUBCUTANEOUS MASTECTOMY TO PREVENT THE DEVELOPMENT OF BREAST-CANCER [J].

GOODNIGHT, JE ;

QUAGLIANA, JM ;

MORTON, DL .

JOURNAL OF SURGICAL ONCOLOGY, 1984, 26 (03) :198-201

[7] Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers [J].

Hartmann, LC ;

Sellers, TA ;

Schaid, DJ ;

Frank, TS ;

Soderberg, CL ;

Sitta, DL ;

Frost, MH ;

Grant, CS ;

Donohue, JH ;

Woods, JE ;

McDonnell, SK ;

Vockley, CW ;

Deffenbaugh, A ;

Couch, FJ ;

Jenkins, RB .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (21) :1633-1637

[8] Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer [J].

Hartmann, LC ;

Schaid, DJ ;

Woods, JE ;

Crotty, TP ;

Myers, JL ;

Arnold, PG ;

Petty, PM ;

Sellers, TA ;

Johnson, JL ;

McDonnell, SK ;

Frost, MH ;

Jenkins, RB .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) :77-84

[9] Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. [J].

Kauff, ND ;

Satagopan, JM ;

Robson, ME ;

Scheuer, L ;

Hensley, M ;

Hudis, CA ;

Ellis, NA ;

Boyd, J ;

Borgen, PI ;

Barakat, RR ;

Norton, L ;

Offit, K .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (21) :1609-1615

[10] Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation [J].

Klaren, HM ;

van't Veer, LJ ;

van Leeuwen, FE ;

Rookus, MA .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (13) :941-947

← 1 2 →